These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7798300)

  • 21. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
    Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
    Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Cameron DA; Leonard RC
    J Natl Cancer Inst; 1999 Apr; 91(8):728-9. PubMed ID: 10218517
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
    Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer.
    Barbati A; Cosmi EV; Sidoni A; Collini P; Porpora MG; Ferri I; Lüthy M; Lauro V; Bucciarelli E
    Anticancer Res; 1997; 17(1A):401-5. PubMed ID: 9066684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
    Gago FE; Tello OM; Diblasi AM; Ciocca DR
    J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
    J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
    Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
    Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
    Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
    J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic importance of p53 and c-erbB-2 oncoproteins overexpression in patients with breast cancer.
    Chariyalertsak S; Chariyalertsak S; Cheirsilpa A; Chindavijak K
    J Med Assoc Thai; 1998 Sep; 81(9):698-704. PubMed ID: 9737128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.